1. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology, 25 (1997) 658-63.
2. Ader JL, Rostaing L: Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. Current Opinion in Nephrology and Hypertension, 7 (1998) 539-545.
3. Aleksic I, Baryalei M, Busch T: Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.
Transplantation, 69 (2000) 1586-1590.
4. Allison AC, Almquist SJ, Muller CD, Eugui EM: In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug RS-61443. Transplant Proc, 23 suppl. 2 (1991) 10-14.
5. Allison AC, Eugui EM: Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplantation, 7 (1993) 96-112.
6. Allison AC, Hovi T, Watts RWE, Webster ADB: Immunological observations on patients with the Lesh Nyhan syndrome, and the role of de novo purine synthesis in lymphocyte transformation. Lancet, ii (1975) 1179-1183.
7. Allison AC, Kowalski WJ, Muller CJ, Waters RV, et al.: Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc, 25 (1993) 67-70.
8. American Society of Hospital Pharmacists, AHFS Drug information., Bethesda, MD, 1993.
9. Barkmann A, Nashan B, Schmidt HHJ: Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation, 69 (2000) 1886-1890.
10. Barry JM: Immunosuppressive drugs in renal transplantation. Drugs, 9 (1992) 104.
11. Bennet WM: Clinical algorithms for cyclosporine management based on pathophysiologic constructs of nephrotoxicity. Transplant Proc, 26 (1994) 2583-4.
12. Benson A, Ziegler HK: Macrophages as targets for inhibition by cyclosporine.
Transplantation, 47 (1989) 696.
13. Billingham RE, Krohn PL, Medawar PB: Effect of cortisone on survival of skin homografts in rabbits. Brit. Med. J., 1 (1951) 1157.
14. Blohmé I, Brynger H: Malignant disease in renal transplant patients. Transplantation, 39 (1985) 23.
15. Borel JF, Feurer C, Gubler HU, Stahelin H: Biological effects of cyclosporin A: a new antilymphotic agent. Agents Actions, 5 (1976) 486.
16. Burdmann EA, Young B, Andoh TF, Evans A, et al.: Mechanisms of cyclosporine-induced interstitial fibrosis. Transplant Proc, 26 (1994) 2588-9.
17. Busuttil RW, McDiarmid S, Klintmalm GB: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med, 331 (1994) 1110.
18. Busuttil RW, Shaked A, J.M. M: One thousand liver transplants: the lesson learned.
Ann Surg, 219 (1994) 490.
19. Cai TH, Esterl RM, Nichols L: Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation.
Transplant Proc, 30 (1998) 1413-1414.
20. Calmus Y, Conti F, Dousset B, Houssin D: Hepatic allograft rejection. Diagnostic and therapeutic aspects. Therapie, 47 (1992) 265-272.
21. Calne RY: The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurin.
Lancet, 1 (1960) 417.
22. Calne RY, Murray JE: Inhibition of the rejection of renal homografts in dogs by Burroughs-Wellcome 57-322. Surg. Forum., 12 (1961) 118.
23. Calne RY, White DJG: Cyclosporin A - a powerful immunosuppressant in dogs with renal allografts. IRCS J Med Sci, 5 (1977) 595.
24. Calne RY, White DJG, Thiru S: Cyclosporine A in patients receiving renal allografts from cadaver donors. Lancet, 2 (1978) 1323.
25. Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporin in cadaveric renal transplantation. N Eng J Med, 309 (1983) 809.
26. Canafax DM, Sutherland DER, Simmons RL, Fryd DS, et al.: Combination immunosuppression: three drugs (azathioprin, cyclosporine, prednisone) for mismatched related and four drugs (antilymphocyte globulin, azathioprin, cyclosporine, prednisone) for cadaver renal allograft recipients. Transplant Proc, 17 (1985) 2671.
27. Cardenas ME, Sanfridson A, Cutler NS, Heitman J: Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol, 16 (1998) 427-33.
28. Chapuis AG, Paolo Rizzardi G, D'Agostino C, Attinger A, et al.: Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo.
Nat Med, 6 (2000) 762-8.
29. Danowitch G, Deierhoi M, Ferguson R: Mycophenolate Mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation, 61 (1996) 722-729.
30. De Vecchi A, Cantaluppi A, Montagino G, Tarantino A, et al.: Long-term comparison between single-morning daily and alternate-day steroid treatment in cadaver kidney recipients. Transplant Proc, 12 (1980) 327.
31. Dempster WJ: The effects of cortisone on the homotransplanted kidney. Arch. Intern.
Pharmacodynam, 95 (1953) 253.
32. Di Bisceglie AM: Liver transplantation for hepatitis C : the promise and the challenge.
Hepatology, 22 (1995) 660-662.
33. Dische FE, Neuberger J, Keating J: Kidney pathology in liver allograft recipients after long-term treatment with cyclosporine A. Lab Invest, 58 (1988) 395.
34. Dureau G, Obadia JF, Chuzel M, Boissonnat P: Introduction of mycophenolate mofetil and cyclosporine withdrawel in heart transplant patients with progressive deteriorating renal function. Transplant Proc, 32 (2000) 461-462.
35. Eckhoff DE, Brendan M, McGuire: Tacrolimus (FK506) and mycophenlate mofetil comination therapy versus tacrolimus in adult liver transplantation. Transplantation, 65 (1998) 180-187.
36. Elion GB: Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purin analogues. Fed Proc, 26 (1967) 898.
37. Elliot JF, Lin Y, Mizel SB, Bleackley RC, et al.: Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science, 226 (1984) 1439.
38. English J, Evan A, Houghton DC, Bennet WM: Cyclosporine induced acute renal dysfunction in the rat. Transplantation, 44 (1987) 135-41.
39. Epinetti WW, Parker CM, Jones FL, Grilst MC: Mycophenolic acid for psoriasis. A review of Pharmacology, long-term efficacy and safety. J Am Acad Dermatol, 17 (1987) 962-971.
40. Eugui EM, Almquist S, Muller CD, Allison AC: Lymphocyte-selective cytostatic and immunosupprissive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol, 33 (1991) 161-173.
41. Eugui EM, Mirkovich A, Allison AC: Lymphocyte selective antiproliferative and immunosuppressive efects of mycophenolic acid in mice. Scand J Immunol, 33 (1991) 175-183.
42. European Multicenter Trial Group: Cyclosporin in cadaveric renal transplantation:
one-year follow-up of a multicentre trial. Lancet, 2 (1983) 986.
43. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet, 345 (1995) 1321-5.
44. Eurotransplant IF, Annual Report, Preliminary data 1997, Leiden, the Netherlands, 1997.
45. Eurotransplant IF, Annual Report, Preliminary data 1999, Leiden, the Netherlands, 1999.
46. Feray C, Samuel D, Thiers V: Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest, 89 (1992) 1361-1365.
47. Feutren G, Mihatsch MJ: Risk factors for CsA-induced nephropathy in patients with autoimmune diseases. N Engl J Med, 326 (1992) 1654.
48. Franklin TJ, Cook JM: The inhibition of nucleic acid synthesis by mycophenolic acid.
Biochem J, 113 (1969) 515-524.
49. Gaber LW, Moore LW, Reed L, Russel W: Renal histology with varying FK506 blood levels. Transplant Proc, 29 (1997) 186.
50. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, et al.: A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology, 110 (1996) 167-77.
51. Garcia RC, Leoni P, Allison AC: Control of phosphoribosyl pyrophosphate synthesis in human lymphocytes. Biochem Biophys Res Commun, 77 (1977) 1067-1073.
52. Gavlik A, Goldberg MG, Tsaroucha A: Mycophenolate mofetil rescue therapy in liver transplant recipients. Transplant Proc, 29 (1997) 549-552.
53. Gibson T, Medawar PB: The fate of skin homografts in man. J. Anat., 77 (1943) 299.
54. Gomez EC, Menendez L, Frost P: Efficacy of mycophenolic acid for treatment of psoriasis. J Am Acad Dermatol, 1 (1979) 531-537.
55. Gong ZJ, De Meyer S, Clarysse C, Verslype C, et al.: Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat, 6 (1999) 229-36.
56. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, et al.: Impact on pretransplant renal function on survival after liver transplantation. Transplantation, 59 (1995) 361.
57. Gorer PA, Lyman S, Snell GD: Studies on the genetic and antigenic basis of tumour transplantation. Linkage between an histocompatibility gene and "fused" in mice.
Proc. Roy. Soc. Lond., 135 (1948) 499.
58. Gupta AK, Rocher LL, Schmaltz SP, Goldfarb MT, et al.: Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Arch Intern Med, 151 (1991) 356-62.
59. Halloran PE, Urmson J, Farkas S, Phillips RA, et al.: Effects of cyclosporine on systemic MHC expression. Evidence that non-T cells produce interferon-gamma in vivo and are inhibitable by cyclosporine. Transplantation, 46 (1988) 68S.
60. Hanke JH, Nichols LN, Coon ME: FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. Lymphokine Cytokine Res, 11 (1992) 221-31.
61. Hayes JM: The immunobiology and clinical use of current immunosuppressive therapy for renal transplantation. journal of urology, 149 (1993) 437-448.
62. Haynes RC: Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones., , New York, 1990, p 1431 pp.
63. Hemenway CS, Heitman J: Calcineurin. Structure, function, and inhibition. Cell Biochem Biophys, 30 (1999) 115-51.
64. Henry ML, Sommer BG, Ferguson RM: Beneficial effects of cyclosporine compared with azathioprin in cadaveric renal transplantation. Amer J Surg, 150 (1985) 533.
65. Herrero IJ, Duiroga J, Sangro B: Conversion of Liver Transplant Recipients on Cyclosporine with Renal Impairment to Mycophenolate Mofetil. Liver Transplant and Surgery, 5 (1999) 414-420.
66. Hollander AAMJ, van Saase JLCM, Koote AMM: Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet, 345 (1995) 610.
67. Ichimura H, Levy JA: Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology, 211 (1995) 554-60.
68. Japanese TAC Study Group: Japanese study of TAC on kidney transplantation: results of an early phase II study. Transplant Proc, 23 (1991) 3071-3074.
69. Jarowenko MV, Flechner SM, Van Buren CT, Lorber MI, et al.: Influence of cyclosporine on posttransplant blood pressure response. Amer J Kidney Dis, 10 (1987) 98.
70. Johnston I, Paterson A: Benign intracranial hypertension. I. Diagnosis and prognosis.
Brain, 97 (1974) 289.
71. Kahan B: Cyclosporine. N Engl J Med, 321 (1989) 1725.
72. Kelso A, Munck A: Glucocorticoid inhibition of lymphokine secretion by alloreactive T lymphocyte clones. J Immunol, 133 (1984) 784.
73. Keown P: A blinded, randomized clinical trial of Mycophenolate Mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation, 61 (1996) 1029-1037.
74. Kino T, Inamura N, Sakai F: Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc, 19 (1987) 36-39.
75. Klintmalm GB, Ascher NL, Busuttil RW: RS-61443 for treatment-resistant human liver rejection. Transplant Proc, 25 (1993) 697.
76. Klupp J, Bechstein WO, Platz KP: Mycophenolate mofetil added to immunosuppression after liver transplantation-first results. Transplant Int, 10 (1997) 223-228.
77. Lan NC, Karin M, Nguyen T, Weisz A, et al.: Mechanisms of glucocorticoid hormone action. J Steroid Biochem, 20 (1984) 77.
78. Laskow DA, Deierhoi MH, Orr C: The incidence of acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443). Transplantation, 57 (1994) 640-643.
79. Lee WA, Gu L, Mikszatai AR, Chi N, et al.: Bioavailability improvement of mycophenolic acid through amino ester derivilisation. Pharmaceutical Research, 7 (1990) 161-166.
80. Liu J, Farmer JJ, Lane WS, Friedman J, et al.: Calcineurin is a common target of cyclophilin-Cyclosporin A and FKBP-FK506 complexes. Cell, 66 (1991) 807-815.
81. Margolis D, Heredia A, Gaywee J, Oldach D, et al.: Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr, 21 (1999) 362-70.
82. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, et al.: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.
Transplantation, 64 (1997) 436-43.
83. McCauley J: The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens, 2 (1993) 662-669.
84. McKenzie N, Keown P, Stiller C: Effects o cyclosporine on renal function following orthotopic heart transplantation. J Heart Transplant, 4 (1985) 400.
85. McManus R, Ohair D, Schwriger J: Cyclosporine-associated central neurotoxicity after heart transplantation. Ann Thorac Surg, 53 (1992) 326.
86. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, et al.: The Side effects of ciclosporine-A and tacrolimus. Clinical Nephrology, 49 (1998) 356-363.
87. Mihatsch MJ, Steiner K, Abeywickrama KH, Landmann TG: Risk factors for the development of chronic cyclosporine-nephrotoxicity. Clin Nephrol, 29 (1988) 165-75.
88. Millis JM, Woodle ES, Piper JB: Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation, 61 (1996) 1365.
89. Mitsui A, Suzuki S: Immunosuppressive effect of mycophenolic acid. Journal of Antibiotics, 22 (1969) 358-363.
90. Moll C, Kahler C, Edis C, Nachbauer K, et al.: Early-level hepatitis C viremia after orthotopic liver transplantation is of prognostic significance. Transplant Proc, 30 (1998) 698-700.
91. Monsour HP, Wood RP, Dyer CH, Galati JS, et al.: Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis, 15 (1995) 123.
92. Mora NP, Klintmalm GB, Solomon H: Survival after liver transplantation in 300 consecutive patients: the influence of age, clinical status, and pretransplant disease.
Transplant Proc, 24 (1992) 156.
93. Morozumi K, Thiel G, Albert FW, Banfi G, et al.: Studies on morphological outcome of cyclosporine-associated ateriolopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol, 38 (1992) 1-8.
94. Morris RE, Wang J, Blum JR: Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant proc, 23 Suppl. 2 (1991) 19-25.
95. Myers BD, Ross J, Newton L, Luetscher J, et al.: Cyclosporin-associated chronic nephropathy. N Engl J Med, 311 (1984) 699-705.
96. Neuhaus P, Bechstein WO, Blumhardt G: Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet, 334 (1994) 423.
97. Neuhaus P, Blumhardt G, Bechstein WO: Comparison of FK506 and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. Transplantation, 59 (1995) 31.
98. Neyts J, Meerbach A, McKenna P, De Clercq E: Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections.
Antiviral Res, 30 (1996) 125-32.
99. Oshugi Y, Suzuki S, Takagaki Y: Antitumor and immunosuppressive effects of mycophenolic acid derivatives. Cancer Res 1976, 36 (1976) 2923-2927.
100. Ost L, Tyden G, Fehrman I: Impaired glucose tolerance in cyclosporine-prednisolone-treated renal graft recipients. Transplantation, 46 (1988) 370.
101. Papatheodoridis GV, O'Beirne J, Mistry P: Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation, 68 (1999) 155-157.
102. Pascual M, Williams WW, Cosimi AB: Chronic renal allograft dysfunction: a role for mycophenlate mofetil. Transplantation, 69 (2000) 1749-1750.
103. Penn I: Cancers following cyclosporine therapy. Transplantation, 43 (1987) 32.
104. Pichlmayr P, et al ftEMMCSG: Placebo controlled study of mycophenlate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection.
Lancet, 345 (1995) 1321-25.
105. Pichlmayr R, Wonigeit K: Immunologie, Grundlagen-Klinik-Praxis, , Thieme Verlag, Stuttgart, New York, 1991.
106. Platz KP, Mueller AR, Willimski C, Mansoorian B, et al.: Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. Transplant Proc, 30 (1998) 1468-9.
107. Romero F, Rodriguez-Iturbe B, Parra G: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int, 55 (1999) 945.
108. Rossi SJ, Schroeder TJ, Hariharan S, First MR: Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf, 9 (1993) 104.
109. Rostaing L, Izopet J, Sandres K, Cisterne JM, et al.: Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation, 69 (2000) 991-4.
110. Rostaing L, Tran-Van T, Cisterne JM, Tack I: Early post- transplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. Transplant Proc, 30 (1998) 1279-1281.
111. Roth D, Zucker K, Cirocco R, Burke G, et al.: A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation, 61 (1996) 886-9.
112. Rudich SM, Riegler JL, Perez RV: Immunosupression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single center experience. Transplant Proc, 30 (1998) 1417-1418.
113. Ruiz JO, Simmons RL, Callendar CO, Kjellstrand CM, et al.: Steriod diabetes in renal transplant recipients: pathogenetic factors and prognosis. Surgery, 73 (1973) 759.
114. Sánchez V, Delgado JF, Blasco T: Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy. Transplant Proc, 31 (1999) 2515-2516.
115. Sandborn WJ, Hay JE, Porayko MK: Cyclosporine withdrawel for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology, 19 (1994) 925.
116. Schreiber SL: Chemistry and biology of the immunophilins and their immunosupressive ligands. Science, 251 (1991) 283-287.
117. Schwartz R, Damashek W: Drug induced immunological tolerance. Nature, 183 (1962) 1682.
118. Shevach EM: The effects of cyclosporine A on the immune system. Ann. Rev.
Immunol., 3 (1985) 397.
119. Simonsen M, Buemann J, Gammeltaft A: Biological incompatibility in kidney transplantation in dogs. I. Experimental and morphological investigations. Acta Path.
Microbiol. Scand., 32 (1953) 1.
120. Singh N, Gayowski T, Ndimbie OK, Nedjar S, et al.: Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. Surgery, 119 (1996) 452-6.
121. Snyder DS, Unanue ER: Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 produktion. J Immunol, 129 (1982) 1803.
122. Sollinger HW, Deierhoi MH, Belzer FO: RS-61443 a phase I clinical trial and pilot rescue study. Transplantation, 53 (1992) 428-432.
123. Sollinger HW, Group ftUSRTMMS: Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation, 60 (1995) 225-232.
124. Starzl TE: Liver Transplantation. Gastroenterology, 112 (1997) 288-291.
125. Starzl TE, Klintmalm GBG, Porter KA: Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med, 305 (1981) 266.
126. Starzl TE, Marchioro TL, Porter KA: The use of heterologous antilymphoid agents in canine renal and liver homotransplantation. Surg. Gynecol. Obstet., 124 (1967) 301.
127. Starzl TE, Marchioro TL, von Kaulla KN, Herrmann G, et al.: Homotransplantation of the liver in humans. Surgery Gynecology and Obstetrics, 117 (1963) 385-395.
128. Starzl TE, Todo S, Fung J, Demetris AJ, et al.: FK506 for liver, kidney, and pancreas transplantation. Lancet (1989) ii: 1000-1004.
129. The Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med, 314 (1986) 1219.
130. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation, 61 (1996) 1029-37.
131. Vathsala A, Weinberg RB, Schoenberg L, Grevel J, et al.: Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation, 48 (1989) 37.
132. Wang SC, Jordan ML, Tweardy DJ, Wright J, et al.: FK-506 inhibits proliferation and IL-4 messenger RNA production by a T- helper 2 cell line. J Surg Res, 53 (1992) 199-202.
133. Weir MR, Anderson L, Fink JC : A novel approach to the treatment of chronic allograft nephropathy. Transplantation, 64 (1997) 1706-1710.
134. Wombolt DG, McCune TR, Stewart M: Use of mycophenolate mofetil in patients with chronic cyclosporine nephrotoxicity. Transplant Proc, 30 (1998) 1194.
135. Woodle ES, Thistlethwaite R, Gordon JH, Laskow D, et al.: A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection.
Tansplantation, 62 (1996) 594-599.
136. Wu J: Mycophenolate mofetil: molecular mechanisms of action. Perspect Drug Discov Design, 2 (1994) 185-204.